Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
May 13, 2024 10:15 ET (14:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations